PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10960075-0	2000	The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway.	SB 203580	29-37	nuclear factor kappa B subunit 1	Homo sapiens	47-69	
10960075-4	2000	In fact, 5 and 10 microM SB203580 enhanced rather than inhibited NF-kappaB-mediated promoter activity by 2 fold, which was independent of phosphorylation of the p65 subunit.	SB 203580	25-33	nuclear factor kappa B subunit 1	Homo sapiens	65-74	
10960075-5	2000	The SB203580-mediated increase in NF-kappaB transcriptional activity was associated with enhanced phosphorylation of extracellular signal-regulated kinase (ERK)1/2 and c-Jun N-terminal kinase (JNK), but not p38 kinase.	SB 203580	4-12	nuclear factor kappa B subunit 1	Homo sapiens	34-43	
10960075-6	2000	Overexpression of kinase-deficient mutants belonging to the ERK1/2, JNK, and p38 pathways showed that only dominant-negative Raf-1 abrogated SB203580-enhanced NF-kappaB activity.	SB 203580	141-149	nuclear factor kappa B subunit 1	Homo sapiens	159-168	
10960075-7	2000	This would implicate the involvement of the ERK1/2 pathway in the enhancing effects of SB203580 on NF-kappaB-mediated gene transcription.	SB 203580	87-95	nuclear factor kappa B subunit 1	Homo sapiens	99-108	
10960075-9	2000	SB203580 at higher concentrations activates the ERK pathway, which subsequently enhances NF-kappaB transcriptional activity.	SB 203580	0-8	nuclear factor kappa B subunit 1	Homo sapiens	89-98